EGFR and non-small cell lung carcinoma: It is yet to be determined if the use of evolving first-line EGFR inhibitor combination strategies (either chemotherapy plus osimertinib or amivantamab plus lazertinib [10,11,47,48]) will similarly translate from clinical trial to real-word EGFRm NSCLC settings.